Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06335303 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 322
- Enrollment target
NCT06335303 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 322 participants.
The verdict
NCT06335303, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 322 participants
- Enrollment target
Study Summary
This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study. Participants are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1819479. Participants in 1 group get placebo. Placebo tablets look like BI 1819479 tablets, but do not contain any medicine. Participants take the treatment for 6 months to 1 year. Participants are in the study for up to 1 year and 2 months. During this time, they visit the study site between 10 and 12 times and get up to 11 phone calls from the site staff. At site visits doctors regularly perform breathing tests that measure how well the lungs are working. Researchers compare the results between participants who take BI 1819479 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects.
Interventions
- DRUG BI 1819479
- DRUG Placebo matching BI 1819479
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2024-09-05 |
| Est. Completion | 2026-01-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06335303
The ClinicalTrials.gov registry entry for NCT06335303 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 322 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BI 1819479 is the first listed.
NCT06335303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06335303 about?
NCT06335303 is a clinical study titled "A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)". This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1...
What is the current status of trial NCT06335303?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 322 participants. The study started on 2024-09-05. Estimated completion is 2026-01-16.
What interventions are being tested in trial NCT06335303?
The interventions under investigation include: BI 1819479 (DRUG), Placebo matching BI 1819479 (DRUG).
Who is sponsoring clinical trial NCT06335303?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.